ES2553423T3 - Viroterapia oncolítica para el tratamiento del sarcoma de Ewing - Google Patents

Viroterapia oncolítica para el tratamiento del sarcoma de Ewing Download PDF

Info

Publication number
ES2553423T3
ES2553423T3 ES12735448.8T ES12735448T ES2553423T3 ES 2553423 T3 ES2553423 T3 ES 2553423T3 ES 12735448 T ES12735448 T ES 12735448T ES 2553423 T3 ES2553423 T3 ES 2553423T3
Authority
ES
Spain
Prior art keywords
ewing
sarcoma
treatment
oncolytic virotherapy
virotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12735448.8T
Other languages
English (en)
Inventor
Zoltán KIS
Jeaninne LACROIX
Barbara Leuchs
Monika FRANK-STÖHR
Jörg SCHLEHOFER
Jean Rommelaere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2553423T3 publication Critical patent/ES2553423T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Parvovirus H1 (H1-PV) para uso en un método para el tratamiento de un sarcoma de Ewing.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
10

Claims (1)

  1. imagen1
ES12735448.8T 2011-06-15 2012-06-15 Viroterapia oncolítica para el tratamiento del sarcoma de Ewing Active ES2553423T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11004884 2011-06-15
EP11004884A EP2535055A1 (en) 2011-06-15 2011-06-15 Oncolytic virotherapy for therapy of bone cancer
PCT/EP2012/002539 WO2012171654A1 (en) 2011-06-15 2012-06-15 Oncolytic virotherapy for the therapy of sarcoma

Publications (1)

Publication Number Publication Date
ES2553423T3 true ES2553423T3 (es) 2015-12-09

Family

ID=44910019

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12735448.8T Active ES2553423T3 (es) 2011-06-15 2012-06-15 Viroterapia oncolítica para el tratamiento del sarcoma de Ewing

Country Status (8)

Country Link
US (1) US9333225B2 (es)
EP (2) EP2535055A1 (es)
JP (1) JP5793242B2 (es)
AU (1) AU2012269386B2 (es)
CA (1) CA2832368C (es)
DK (1) DK2720702T3 (es)
ES (1) ES2553423T3 (es)
WO (1) WO2012171654A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2988446C (en) * 2015-06-23 2020-07-21 Deutsches Krebsforschungszentrum Method for large scale production and purification of parvovirus
EP3225253A1 (en) * 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
WO2018119069A1 (en) * 2016-12-21 2018-06-28 Mooberry Susan L Altertoxin ii as a selective inhibitor of ewing family of tumor cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO2003097835A2 (en) * 2002-05-16 2003-11-27 Molecular Engines Laboratories Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
AU2012269386B2 (en) 2015-10-15
CA2832368A1 (en) 2012-12-20
US20140205573A1 (en) 2014-07-24
JP5793242B2 (ja) 2015-10-14
CA2832368C (en) 2017-07-25
EP2720702A1 (en) 2014-04-23
AU2012269386A1 (en) 2013-08-29
EP2720702B1 (en) 2015-06-24
US9333225B2 (en) 2016-05-10
DK2720702T3 (en) 2015-09-07
WO2012171654A1 (en) 2012-12-20
JP2014518206A (ja) 2014-07-28
EP2535055A1 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
ES2644844T3 (es) Mecanismo de soporte
UY4211Q (es) Pizarra para marcadores
ES2643848T3 (es) Método para cuantificar dosis UV desinfectantes usando indicadores
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
MX386224B (es) Activadores de cinasa de piruvato para su uso en terapia.
UY34503A (es) ?sal de bromhidrato de pridopidina?
ES2666397T3 (es) Activación de CD89 en terapia
JP2013531018A5 (es)
UY34792A (es) ?método de uso de profungicidas de uk-2a para control de la roya de soja?.
UY34200A (es) 3-(fluorovinil)pirazoles y su uso
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
ES2611776T3 (es) Uso de sales de tungsteno (VI) para el tratamiento de la esterilidad femenina en mamíferos no diabéticos
ES2633762T3 (es) Hipertensión e hiperuricemia
ES2644847T3 (es) Máquina agrícola
ES2664171T3 (es) Aditivo retardador del fraguado y plastificante para el hormigón
ES2644995T3 (es) Módulo de filtro
ES2565198T3 (es) Metapneumovirus aviar en oncólisis
UY34140A (es) Mejoras en el riego
JP2013073724A5 (es)
ES2536842T3 (es) Composición farmacéutica para el tratamiento del cáncer
UA116372C2 (uk) Частинки резинату фенілефрину
UY34734A (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer.
ES2528962T9 (es) Un procedimiento para secar la colada
ES2585558T3 (es) Uso de sales de 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio en el tratamiento de una enfermedad cardiovascular
CL2014001784A1 (es) Uso de compuestos derivados de imidazopiridina sustituidos para el tratamiento del cancer de vejiga.